WALD - NASDAQ

Waldencast plc

WALD·NASDAQ

$1.71

-7.1%

TechnologySoftware - Application

Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$202.19M

EPS-2.0100

P/E Ratio-0.85

Earnings Date05/11/2026

816.20M

Assets

-16%

3Y-25.0%

5Y+489251.0%

10Y+489251.0%

316.10M

Total Liabilities

29%

3Y+9.0%

5Y+177741.0%

10Y+177741.0%

500.10M

Total Equity

-31%

3Y-37.0%

5Y-4566788.0%

10Y-4566788.0%

Waldencast plc Funding & Solvency Profile

WALD · NASDAQ

Current Assets

Cash & Cash Equivalents31.89M

Net Receivables29.23M

Inventory54.61M

Other Current Assets4.81M

Total Current Assets127 M

Non-Current Assets

Property, Plant & Equipment13.97M

Goodwill & Intangible Assets604.67M

Long-Term Investments0.00

Other Non-Current Assets574.00K

Total Non-Current Assets15 M

Total Assets

816.20M

Financial Health Analysis

Current Ratio

1.70x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

0.63x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

52 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

16% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Waldencast plc Balance Sheet

WALD • NASDAQ

Waldencast plc Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	31.9M	14.8M	22.6M	8.7M	12.8M	0.0
Cash & Short-Term Investments	31.9M	14.8M	22.6M	8.7M	12.8M	0.0
Net Receivables	29.2M	26.3M	22.4M	19.5M	18.7M	0.0
Accounts Receivables	28M	25.5M	21.3M	19.3M	18.7M	0.0
Other Receivables	1.2M	792K	1.1M	285K	0.0	0.0
Inventory	54.6M	53.1M	55.7M	54.4M	21.6M	0.0
Prepaids	6.4M	7.5M	5.3M	6.3M	5M	0.0
Other Current Assets	4.8M	1.9M	1.4M	2.1M	929K	166.8K
Total Current Assets	126.9M	103.6M	107.3M	91M	59M	166.8K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	14M	15.7M	17.5M	24.7M	1.2M	0.0
Goodwill	177.6M	329.6M	334.6M	334.6M	44.5M	0.0
Intangible Assets	427.1M	526.4M	582.9M	639.2M	79.6M	0.0
Goodwill & Intangible Assets	604.7M	856M	917.5M	973.8M	124.1M	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	345.1M	0.0
Tax Assets	70M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	574K	541K	380K	535K	-344.8M	166.8K
Total Non-Current Assets	689.3M	872.2M	935.4M	999M	125.5M	166.8K
Other Assets	0.0	0.0	0.0	0.0	0.0	-166.8K
Total Assets	816.2M	975.9M	1B	1.1B	184.6M	166.8K
LIABILITIES
CURRENT LIABILITIES
Total Payables	23.1M	25.1M	28.1M	24.2M	12.7M	177.7K
Accounts Payable	19.5M	25.1M	28.1M	24.2M	12.7M	177.7K
Other Payables	3.6M	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	4.9M	17.1M	0.0	14.6M	6.9M	0.0
Short Term Debt	2.9M	29.5M	8.5M	20.1M	15.4M	0.0
Capital Lease Obligations (Current)	0.0	2.8M	2.4M	2M	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	10.3M	0.0	0.0
Other Current Liabilities	43.7M	2.4M	23.7M	1.2M	5.8M	0.0
Total Current Liabilities	74.5M	76.9M	62.7M	72.5M	40.8M	177.7K
NON-CURRENT LIABILITIES
Long Term Debt	135.8M	137.1M	151.3M	159.2M	103.4M	0.0
Deferred Tax Liabilities (Non-Current)	73.1M	14M	15.2M	22.3M	548K	0.0
Other Non-Current Liabilities	22.3M	5.1M	28.7M	18.3M	571K	0.0
Total Non-Current Liabilities	241.6M	169M	210.7M	217.7M	104.5M	0.0
Capital Lease Obligations	10.4M	15.5M	17.9M	19.9M	0.0	0.0
Total Liabilities	316.1M	245.9M	273.4M	290.2M	145.3M	177.7K
SHAREHOLDERS' EQUITY
Common Stock	13K	12K	11K	10K	4M	863.0
Additional Paid-In Capital	981.2M	951.3M	871.5M	796M	100.1M	0.0
Retained Earnings	-519M	-289.2M	-246.8M	-156.8M	-64.8M	-11K
Accumulated Other Comprehensive Income/Loss	-378K	251K	-151K	-29K	-25K	0.0
Total Stockholders' Equity	461.9M	662.3M	624.6M	639.2M	39.2M	-11K
Total Equity	500.1M	729.9M	769.3M	799.9M	39.2M	-11K
Minority Interest	38.2M	67.6M	144.6M	160.7M	0.0	0.0
SUMMARY
Total Liabilities & Equity	816.2M	975.9M	1B	1.1B	184.6M	166.8K
Total Investments	0.0	0.0	0.0	0.0	345.1M	0.0
Total Debt	149M	182.1M	177.7M	199.2M	118.9M	0.0
Net Debt	117.1M	167.3M	155.1M	190.6M	106.1M	0.0
Shares Outstanding	112,011,451	112,011,451	112,011,451	112,011,451	112,011,451	112,011,451

SEC Filings

WALD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
6-K 6-K 2026 Q2 Q2	June 01, 2026	June 01, 2026	2026	View Filing
6-K 6-K 2026 Q2 Q2	April 28, 2026	April 28, 2026	2026	View Filing
6-K 6-K 2025 Q4 Q4	March 13, 2026	December 31, 2025	2025	View Filing
20-F 20-F 2025 FY FY	March 13, 2026	December 31, 2025	2025	View Filing
6-K 6-K 2025 Q4 Q4	March 11, 2026	December 31, 2025	2025	View Filing
6-K 6-K 2026 Q1 Q1	January 15, 2026	January 15, 2026	2026	View Filing
6-K 6-K 2025 Q4 Q4	December 19, 2025	December 19, 2025	2025	View Filing
6-K 6-K 2025 Q3 Q3	November 24, 2025	September 30, 2025	2025	View Filing
6-K 6-K 2025 Q2 Q2	November 24, 2025	June 30, 2025	2025	View Filing
6-K 6-K 2025 Q4 Q4	November 14, 2025	November 14, 2025	2025	View Filing

Showing 1 to 10 of 86 filings

Related Guides

Blog Categories

Continue your WALD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.